However, likely due to the critical challenges in identifying clinically relevant CD4+ epitopes in the often HLA-II negative GBM tumors (9), the inclusion of CD4+ epitopes in anti-GBM vaccines has been very limited, and consequently, the characterization of antigen-specific CD4+-mediated T responses was lagging behind. The gene discussed is CD4; the disease is glioblastoma.